Novartis to Buy Myricx Bio for Up to $1.5 Billion

2026-07-06 | original

read original more articles

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

Explore topics: based biotechnology biotechnology biotechnology firm bolster bolster novartis